TSK reported a 2Q24 update outlining continued strong momentum regarding client wins, deployments and cash flows. We maintain our Buy recommendation and reduce our Price Target to $0.57/sh (previously $0.62/sh).
Clinuvel (CUV) is one of very few ASX-listed biopharma companies directly commercialising novel pharmaceuticals across the US and EU in a highly profitable manner. We initiate coverage with a Buy rating and a Price Target of PT $24.00.
Eagers announced it has entered into a non-binding agreement to acquire a portfolio of dealerships and key strategic properties located across Melbourne and the Mornington region of Victoria from a group of companies associated with Nick Politis.
In this note we review the most recent indicators for GNC near term and the attractiveness of expanding oilseed crush capacity in the medium term in light of through the cycle canola acreage and production expansion. Our Buy rating remains unchanged.